| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
British
Thoracic Society Research Committee
Correspondence to: Dr S Elborn, Adult Cystic Fibrosis Centre, Level 11, Belfast City Hospital, Belfast BT9 7AB, UK email:stuart.elborn{at}bch.n-i.nhs.uk
Received 14 August 1998; Returned to authors 9 December 1998; Revised version received 6 August 1999; Accepted for publication 5 October 1999
BACKGROUND
A
previous retrospective study suggested that a policy of regular
anti-pseudomonal antibiotic treatment improved pulmonary function and
increased survival in patients with cystic fibrosis chronically
infected with Pseudomonas species. The
results of a prospective multicentre study to compare the effects on
pulmonary function and mortality of three monthly elective
anti-pseudomonal antibiotic treatment with conventional symptomatic
treatment are reported.
METHODSSixty patients
with cystic fibrosis, chronically infected with P
aeruginosa, were randomised to the two treatment arms (elective or symptomatic) and followed clinically at yearly reviews. The major
end points were changes in forced expiratory volume in one second
(FEV1) and forced vital capacity (FVC). Survival was a secondary end point.
RESULTSPatients
in the symptomatic group received a mean of three antibiotic treatments
each year and those in the elective group received four antibiotic
treatments during each year of the study. No significant differences in
FEV1 and FVC were found between the two groups after three
years. There was a statistically non-significant higher rate of deaths
in the elective group (n = 4), three of which were associated with
B cepacia infection, compared with the
symptomatic group (n = 0).
CONCLUSIONSThis study
did not demonstrate an advantage of a policy of elective antibiotic
treatment over symptomatic treatment in patients with cystic fibrosis
chronically infected with Pseudomonas species.
This article has been cited by other articles:
|
|
 |
|
  S. C Bell and P. J Robinson Exacerbations in cystic fibrosis: 2 {middle dot} Prevention Thorax, August 1, 2007; 62(8): 723 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W Southern Acute renal failure in people with cystic fibrosis Thorax, June 1, 2007; 62(6): 472 - 473. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kraemer, A. Blum, A. Schibler, R. A. Ammann, and S. Gallati Ventilation Inhomogeneities in Relation to Standard Lung Function in Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., February 15, 2005; 171(4): 371 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. J M Doull Recent advances: Recent advances in cystic fibrosis Arch. Dis. Child., July 1, 2001; 85(1): 62 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. ROSEBY, J. MASSIE, and S ELBORN Pseudomonas infection in CF Thorax, December 1, 2000; 55(12): 1070b - 1070. [Full Text]
|
|
|
|
|
|
N HØIBY and C KOCH Maintenance treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis Thorax, May 1, 2000; 55(5): 349 - 350. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
